How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 76.9 | 76.9 | 76.9 | 77.6 | 77.6 | 77.6 | +0.7 |
| Healthcare | 17.8 | 17.8 | 17.8 | 17.7 | 17.7 | 17.7 | -0.1 |
| Chemicals | 1.3 | 1.3 | 1.3 | 1.2 | 1.2 | 1.2 | -0.2 |
| Unclassified | · | · | · | 0.7 | 0.7 | 0.7 | 0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 12.69% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DRREDDY | Pharma | 8.45% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| CIPLA | Pharma | 6.56% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| DIVISLAB | Pharma | 6.03% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| MANKIND | Pharma | 5.47% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| ALKEM | Pharma | 5.11% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| BIOCON | Pharma | 4.97% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| COHANCE | Healthcare | 3.92% | 4 | 5 | 6 | 3 | 5 | — | +1.5% |
| MEDPLUS | Pharma | 3.80% | 2 | 4 | 5 | 4 | 7 | — | -27.0% |
| SYNGENE | Healthcare | 3.26% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
| MAXHEALTH | Healthcare | 2.81% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| ABBOTINDIA | Pharma | 2.63% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| APLLTD | Pharma | 2.43% | 4 | 5 | 10 | 2 | 9 | — | +2.8% |
| BLUEJET | Pharma | 2.39% | 8 | 10 | 3 | 10 | 4 | — | +21.8% |
| LUPIN | Pharma | 2.23% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| PFIZER | Healthcare | 1.97% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| THYROCARE | Pharma | 1.95% | 7 | 10 | 8 | 9 | 2 | — | +1.4% |
| AKUMS | Pharma | 1.89% | 8 | 3 | 4 | 2 | 3 | — | +33.9% |
| ASTRAZEN | Pharma | 1.86% | 2 | 5 | 2 | 1 | 6 | — | -22.3% |
| ENTERO | Healthcare | 1.72% | 10 | 7 | 8 | 2 | 2 | — | +65.2% |
| RAINBOW | Healthcare | 1.51% | 10 | 7 | 4 | 3 | 4 | — | +5.0% |
| METROPOLIS | Pharma | 1.49% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| ALIVUS | Pharma | 1.33% | 8 | 4 | 4 | 9 | 5 | — | +34.2% |
| MEDIASSIST | Healthcare | 1.27% | 4 | 7 | 9 | 8 | 7 | — | -8.2% |
| HIKAL | Pharma | 1.18% | 6 | 1 | 6 | 1 | 4 | — | +30.7% |
| FINEORG | Chemicals | 1.18% | 6 | 5 | 3 | 5 | 4 | — | +4.8% |
| AARTIDRUGS | Pharma | 1.16% | 9 | 4 | 6 | 7 | 7 | — | +11.1% |
| AUROPHARMA | Pharma | 0.81% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| WINDLAS | Pharma | 0.75% | 9 | 7 | 5 | 1 | 4 | — | +37.4% |
| FDC | Pharma | 0.74% | 3 | 5 | 2 | 8 | 8 | — | -14.7% |
| INDOCO | Pharma | 0.54% | 10 | 2 | 4 | 6 | 6 | Leader | +21.2% |
| JLHL | Healthcare | 0.47% | 1 | 9 | 4 | 2 | 10 | — | -83.0% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹200 (+100%), vs ₹156 for Nifty 500 (+56%) and ₹137 for Nifty 50 (+37%). Its relative-strength line ended at 146 vs Nifty 50 and 128 vs Nifty 500 — above 100, sustained outperformance.